Steward Partners Investment Advisory LLC Grows Stake in Hologic, Inc. (NASDAQ:HOLX)

Steward Partners Investment Advisory LLC raised its stake in Hologic, Inc. (NASDAQ:HOLX) by 5.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,398 shares of the medical equipment provider’s stock after acquiring an additional 1,338 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Hologic were worth $1,831,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HOLX. Swedbank AB boosted its stake in Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after acquiring an additional 306,562 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of Hologic by 27.4% in the third quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical equipment provider’s stock valued at $164,000 after purchasing an additional 434 shares during the period. Van ECK Associates Corp bought a new stake in shares of Hologic in the third quarter valued at approximately $725,000. Principal Financial Group Inc. raised its position in shares of Hologic by 3.6% in the third quarter. Principal Financial Group Inc. now owns 269,546 shares of the medical equipment provider’s stock valued at $21,957,000 after purchasing an additional 9,419 shares during the period. Finally, Equitable Trust Co. bought a new stake in shares of Hologic in the third quarter valued at approximately $252,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HOLX has been the topic of several research reports. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Citigroup lowered their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Morgan Stanley lowered their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Hologic presently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $64.54 on Friday. The company’s fifty day moving average price is $68.19 and its 200-day moving average price is $75.30. The firm has a market capitalization of $14.48 billion, a price-to-earnings ratio of 20.36, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a one year low of $61.70 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.